Scripps Research Institute spinout BlackThorn Therapeutics will use Yale's Gemini-Dot technology to identify drug targets for neurobehavioural disorders.

BlackThorn Therapeutics, a US-based neurobehavioural therapy spinout from Scripps Research Institute, has licensed research from Yale University’s School of Medicine. The licence covers a technique dubbed Gemini-Dot which maps correlations between neuroimaging and gene expression in the brain to help identify drug targets and clinical populations. BlackThorn is developing therapies for neurobehavioural conditions such as…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.